IL-33 Antibody [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # AF4810Z
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Western Blot, Immunocytochemistry
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Polyclonal Goat IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
E. coli-derived recombinant human IL-33 Propeptide
Met1-Ser111
Accession # O95760
Met1-Ser111
Accession # O95760
Specificity
Detects human IL-33 Propeptide in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with mature recombinant human IL-33 and mature recombinant mouse IL-33 is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Applications for IL-33 Antibody [DyLight 755]
Application
Recommended Usage
Immunocytochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-33
Long Name
Interleukin 33
Alternate Names
C9orf26, DVS27, IL33, NF-HEV
Gene Symbol
IL33
Additional IL-33 Products
Product Documents for IL-33 Antibody [DyLight 755]
Product Specific Notices for IL-33 Antibody [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...